Platelet activation by low concentrations of intact oxidized LDL particles involves the PAF receptor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 3, 2009, Pages 363-371

  Chen, Rui ^a   Chen, Xi ^b   Salomon, Robert G ^b   McIntyre, Thomas M ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Oxidized ldl; PAF; Paf acetylhydrolase; Phospholipid; Platelet

Indexed keywords

ARACHIDONOYL PHOSPHOLIPID DERIVATIVE; CALCIUM; DOCOSAHEXANEOYL PHOSPHOLIPID DERIVATIVE; FIBRINOGEN RECEPTOR; FURA 2; HEXADECYL AZELAOYL LYSOTHROMBOCYTE ACTIVATING FACTOR RECEPTOR; LOW DENSITY LIPOPROTEIN; LUNOLEOYL PHOSPHOLIPID DERIVATIVE; PADGEM PROTEIN; THROMBIN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; APAFANT; AZEPINE DERIVATIVE; COLLAGEN; ETHER PHOSPHOLIPID; G PROTEIN COUPLED RECEPTOR; LIGAND; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; TRIAZOLE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CELL LABELING; CELL MEMBRANE; CONTROLLED STUDY; FLOW CYTOMETRY; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; LIPID OXIDATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; CALCIUM SIGNALING; DRUG EFFECT; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; THROMBOCYTE; TIME;

ADENOSINE DIPHOSPHATE; AZEPINES; BLOOD PLATELETS; CALCIUM SIGNALING; COLLAGEN; HUMANS; LIGANDS; LIPOPROTEINS, LDL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; P-SELECTIN; PHOSPHOLIPID ETHERS; PHOSPHOLIPIDS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; THROMBIN; TIME FACTORS; TRIAZOLES;

EID: 61549140379     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.178731     Document Type: Article

References (49)

1. Leaver HA, Schou AC, Rizzo MT, Prowse CV. Calcium-sensitive mitochondrial membrane potential in human platelets and intrinsic signals of cell death. Platelets. 2006;17:368-377.
2. Rosado JA, Lopez JJ, Gomez-Arteta E, Redondo PC, Salido GM, Pariente JA. Early caspase-3 activation independent of apoptosis is required for cellular function. J Cell Physiol. 2006;209:142-152.
3. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005:3:2185-2192.
4. Dale GL, Friese P. Bax activators potentiate coated-platelet formation. J Thromb Haemost. 2006;4:2664-2669.
5. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vase Biol. 2005;25:467-471.
6. Jobe SM, Wilson KM, Leo L, Raimondi A, Molkentin JD, Lentz SR, Di Paola J. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111: 1257-1265.
7. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001; 11:93-102.
8. Daub K, Lindemann S, Langer H, Seizer P, Stellos K, Siegel-Axel D, Gawaz M. The evil in atherosclerosis: adherent platelets induce foam cell formation. Semin Thromb Hemost. 2007;33:173-178.
9. Siess W. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb. 2006; 35:292-304.
10. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000;28:1717-1725.
11. Heinecke JW. Cellular mechanisms for the oxidative modification of lipoproteins: implications for atherogenesis. Coron Artery Dis. 1994;5: 205-210.
12. Chen R, Yang L, Mcmtyre TM. Cytotoxic phospholipid oxidation products: Cell death from mitochondrial damage and the intrinsic caspase cascade. J Biol Chem. 2007:282:24842-24850.
13. Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, Castro-Faria Neto H, Prescott SM, Zimmerman GA, McIntyre TM. Inflammatory PAF-like lipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem. 1999:274: 28395-28405.
14. Chen X, Zhang W, Laird J, Hazen SL, Salomon RG. Polyunsaturated phospholipids promote the oxidation and fragmentation of gamma -hydroxyalkenals: formation and reactions of oxidatively truncated ether phospholipids. J Lipid Res. 2008;49:832-846.
15. Dupre DJ, Thompson C, Chen Z, Rollin S, Larrivee JF, Le Gouill C, Rola-Pleszczynski M, Stankova J. Inverse agonist-induced signaling and down-regulation of the platelet-activating factor receptor. Cell Signal. 2007:19:2068-2079.
16. Shen TY, Hwang S-B, Doebber TW, Robbins JC. The chemical and biological properties of PAF agonists, antagonists, and biosynthetic inhibitors. In: Snyder F, ed. Platelet-Activating Factor and Related Lipid Mediators. New York: Plenum Press; 1987: 153-190.
17. Reis A, Domingues MR, Amado FM, Ferrer-Correia AJ, Domingues P. Separation of peroxidation products of diacyl-phosphatidylcholines by reversed-phase liquid chromatography-mass spectrometry. Biomed Chromatogr. 2005;19:129-137.
18. Chong AJ, Pohlman TH, Hampton CR, Shimamoto A, Mackman N, Verrier ED. Tissue factor and thrombin mediate myocardial ischemia reperfusion injury. Ann Thorac Surg. 2003;75:S649-S655.
19. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem. 1991; 266:11104-11110.
20. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086-1095.
21. Pegorier S, Stengel D, Durand H, Croset M, Ninio E. Oxidized phospholipid: POVPC binds to platelet-activating-factor receptor on human macrophages Implications in atherosclerosis. Atherosclerosis. 2005;188: 433-443.
22. Maschberger P, Bauer M, Baumann-Siemons J, Zangl KJ, Negrescu EV, Reininger AJ, Siess W. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J Biol Chem. 2000;275:19159-19166.
23. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272:13597-13607.
24. Tsoukatos DC, Arborati M, Liapikos T, Clay KL, Murphy RC, Chapman MJ, Ninio E. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL. Arterioscler Thromb Vase Biol. 1997;17:3505-3512.
25. Androulakis N, Durand H, Ninio E, Tsoukatos DC. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. J Lipid Res. 2005;46:1923-1932.
26. Greenberg ME, Li XM, Gugiu BG, Gu X, Qin J, Salomon RG, Hazen SL. The lipid whisker model of the structure of oxidized cell membranes, J Chem. 2008;283:2385-2396.
27. Siess W, Zangl KJ, Essler M, Bauer M, Brandi R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA. 1999:96:6931-6936.
28. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987:39:97-145.
29. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Ann Rev Biochem. 2000;69: 419-445.
30. Ishii S, Nagase T, Shimizu T. Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat, 2002;68-69:599-609.
31. O'Flaherty JT, Salzer WL, Cousart S, McCall CE, Piantadosi C, Surles JR, Hammett MJ, Wykle RL. Platelet-activating factor and analogues: Comparative studies with human neutrophils and rabbit platelets. Res Comm Chem Pathol Pharm. 1983;39:291-309.
32. Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, Rothe G, Schmitz G. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res. 2003; 44:754-761.
33. Subbaiah PV, Chen CH, Bagdade JD, Albers JJ. Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction. J Biol Chem. 1985;260:5308-5314.
34. Kajihara A, Komooka H, Kamiya K, Yoneda T, Yoneda S, Nakamura M, Shimizu T, Umeyama H. Three-dimensional model of the human PAF receptor. J Lipid Medial Cell Signal. 1994;9:185-196.
35. Tuominen A, Miller YI, Hansen LF, Kesanjemi YA, Witztum JL, Horkko S. A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arterioscler Thromb Vase Biol. 2006;26:2096-2102.
36. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med. 2006; 203:2613-2625.
37. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, Binder BR, Leitinger N. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte- endothelial interactions. Arterioscler Thromb Vase Biol. 2002-22:101-107.
38. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002;277: 38503-38516.
39. Korporaal SJ, Van Eck M, Adelmeijer J, Ijsseldijk M, Out R, Lisman T, Lenting PJ, Van Berkel TJ, Akkerman JW. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2007;27:2476-2483.
40. Hodis HN, Kramsch DM, Avogaro P, Bittolo-Bon G, Cazzolato G, Hwang J, Peterson H, Sevanian A. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res. 1994;35:669-677.
41. Li R, Mouillesseaux KP, Montoya D, Cruz D, Gharavi N, Dun M, Koroniak L, Berliner JA. Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC. Circ Res. 2006;98: 642-650.
42. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: Oxidatively-fragmented phospholipids as substrates. J Biol Chem. 1991;266:11095-11103.
43. Davis B, Koster G, Douet LJ, Scigelova M, Woffendin G, Ward JM, Smith A, Humphries J, Burnand KG, Macphee CH, Postle AD. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem. 2008;283:6428-6437.
44. Mahfouz MM, Kummerow FA. Oxidized low-density lipoprotein (LDL) enhances thromboxane A(2) synthesis by platelets, but lysolecithin as a product of LDL oxidation has an inhibitory effect. Prostaglandins Other Lipid Mediat. 2000;62:183-200.
45. Bochkov VN, Leitinger N. Anti-inflammatory properties of lipid oxidation products. J Mol Med. 2003;81:613-626.
46. Karabina SA, Ninio E. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochim Biophys Acta. 2006;1761:1351-1358.
47. Gomes RN, Bozza FA, Amancio RT, Japiassu AM, Vianna RC, Larangeira AP, Gouvea JM, Bastos MS, Zimmerman GA, Stafforini DM, Prescott SM, Bozza PT, Castro-Faria-Neto HC. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock. 2006:26:41-49.
48. Ninio E. Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care. 2005;8:123-131.
49. Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol, 2006:6:154-161.